Columbus, OH --- Results of an intensive, United States Trotting Association-funded scientific study intended to ascertain the appropriate regulatory level for determining the excessive presence of the naturally-occurring substance cobalt were announced on Tuesday (Sept. 30). Based upon extensive research, the scientists have concluded that 70 parts per billion in blood is the appropriate regulatory threshold. The recommendation guards against false positives, while identifying those who are engaged in artificial administration with the intent to enhance a horse's performance. "I want to thank Doctors Maylin, McKeever and Malinowski for applying appropriate scientific principles and protocols to achieve a regulatory threshold that is both reasonable for the industry and efficacious in deterring those who would choose to violate it," said USTA President Phil Langley in praising the contingent's diligent efforts. "With substances that are a natural constituent of a horse like cobalt, there is always a fine line between catching the cheaters and protecting innocent horsemen from violation. These scientists worked hard to achieve a proper balance, which should serve as a guidepost for the rest of the industry," added Langley. The USTA Medication Advisory Committee will continue to study the overall effects of cobalt and other substances in the racehorse in greater detail. Research indicates that cobalt stimulates the production of erythropoietin (EPO) to produce red blood cells. Widespread abuse of cobalt by human athletes has been rumored for years, and its purported use in racehorses prompted the USTA to take a highly proactive approach in the prevention of its artificial administration for the purpose of illicit performance enhancement. In June, the USTA contracted with Dr. George Maylin of New York's Drug Testing and Research Program at Morrisville State College to determine at what level cobalt ceases being considered a naturally occurring substance and becomes a clear attempt at performance enhancement. His work was assisted by Director Dr. Karyn Malinowski and Associate Director Dr. Ken McKeever from the Equine Science Center at Rutgers University in New Jersey. Based upon the USTA's funding, Dr. Maylin was able to secure a long-term lease of a specialized state-of-the-art instrument required to conduct proper scientific analysis to determine the presence and levels of cobalt in samples. That new, unique equipment with unrivaled performance differentiates these results from any other scientific study on the artificial introduction of cobalt in horses. It is anticipated that the regulators in several jurisdictions will consider the suggested threshold when the supporting data is released. From the USTA Communications Department
Here at Harnesslink we are constantly trying to bring you updates on all the harness racing and breeding issues affecting our industry. However we feel little or no coverage is given to the multitude of companies and service providers that provide products to the harness racing community. Therefore we thought it was timely to take a look at some of these companies and the products they offer. One of those companies is, APC, Inc., the manufacturer of the new LIFELINE serum-based equine performance products. While mostly unknown in the equine industry, APC is a third-generation family-owned company headquartered in Iowa. This science-based company is a global leader in the fractionation (concentration) of serum and plasma-based proteins. For over 30 years the company has been spearheading discoveries that have improved performance and health of many species of animals including calves, swine, aquaculture and more. With such proven performance in other species, APC realized they could apply these learnings to the equine industry. Everybody in the harness racing industry knows that for the equine athlete, racing, training and travelling takes a significant toll on your horse’s performance. Joint soreness, stomach upset and respiratory issues, often caused by inflammation, have been major factors affecting performance since the inception of this industry. The success of the LIFELINE range of equine products is due to BioThrive™. This active ingredient is made using APC’s proprietary process. Derived from bovine serum, its safety and beneficial effects have been documented in more than 300 published peer reviewed journal articles. These bioactive proteins have been shown to help support a healthy inflammation response. When a horse experiences stress or occasional soreness due to normal training, its immune system springs into action to combat the stressors. This immune system response results in inflammation which can have an effect on the following; Gut - digestive health and related conditions such as ulcers Joint - occasional soreness Respiratory - breathing and lung issues related to exercise Bioactive proteins when given orally help reduce overstimulation of the immune system so the horse's resources aren't spent fighting the stressor and instead can promote a healthy gut, maintain proper joint function and ease respiratory issues related to exercise. Unlike a lot of the products on the market, LIFELINE is not a vitamin or mineral supplement which typically target nutrition and work in just one system at a time. It works multisystemically. It also works fast with studies demonstrating a difference within just fourteen days. LIFELINE has two equine products which are aimed at horses in different stages of their life. Both products have bioactive proteins as their active ingredient, specifically formulated based on the age of the horse. Equine Elite is for horses experiencing the rigors of training and racing. AgeWell is for the older horse who is experiencing the physical effects of aging but are still expected to perform to their best. A recent gait analysis study conducted by Dr. Josie Coverdale and Joy Campbell of Texas A+M University measured stride length and knee range of motion with increasing dosage of serum-based bioactive proteins in exercised horses. The response strongly suggested that the horses in the study experienced healthy joint function and/or comfort while on LIFLINE BioThrive™. This study involved thirty horses over a 28 day period and was a robust academic study in a controlled setting and reinforced the feedback that LIFELINE was receiving daily from its clients. APC is also in various stages of process for a number of other studies on horses to include gut health, training in 2-year old stallions and mare/foal pairs. Results are not finalized but are promising. LIFELINE takes corporate responsibility very seriously. It is a member of the National Animal Supplement Council which is dedicated to protecting and enhancing the health of companion animals and horses The company has also invested in research ensuring that LIFELINE products are show/competition safe. The LIFELINE brand has come a long way over the past few decades. Between its significant investment in R&D, current and upcoming scientific study results and positive testimonials from product users, the future for APC looks assured. All in all I think the company motto says it all about LIFELINE – Watch Them Thrive. http://horse.watchthemthrive.com/ For this months special offer click here. Harnesslink media Lifeline Equine Performance
Schenectady, NY – Harness Racing’s top guns descended upon the New York State Gaming Commission public hearing to advance concerns over proposed drug levels for racehorses. U. S. Trotting Association President, Phil Langley, and Standardbred Owners Association of New York President, Joe Faraldo, led a group of distinguished veterinarians and research experts to counter the “one size fits all” approach being forwarded by the Thoroughbred-based Racing Medication and Testing Consortium (RMTC) proposals. The appearance of the Standardbred leaders at the public hearing, called by the agency formerly known as the NYS Racing and Wagering board, was to hear “testimony about adoption of per se regulatory thresholds for 24 approved equine medications and amending pre-race restricted time periods for various drugs.” One particular therapeutic substance, respiratory aid Clenbuterol, has been at the forefront of a debate over uniform medication rules approved by the RMTC. Although there is widespread Thoroughbred support for the measures, the Standardbred industry has argued that the two breeds have very distinct differences and therefore should be treated differently. The proposed rule would prohibit the bronchial dilator from being administered within 14 days of racing, effectively eliminating its potential benefit to Standardbreds that generally race every week. Langley noted that, “Our horses are so durable, they do not even look [like Thoroughbreds.] Many of our horses race 30 to 40 times each year. In fact, the leading money-winning horse of all time started 198 times. We are not trying to get the standards lowered. We just want to conduct [racing] the way we are.” Dr. Kanter, an expert in equine medicine and pharmacology, with over 40 years of experience as the track vet at Buffalo and Batavia. “This measure could be denying horses the benefit of years of research of these useful therapeutic drugs, while the efficacy of known substitutes is yet unproven.” Dr. Janet Durso of Goshen, NY, reiterated those concerns. “Clenbuterol is one of the best drugs for treating blood and discharge from a horse’s lungs. Remedies would be problematic without it!” One of the contributing factors toward this proposal is the concern that some Thoroughbred trainers are abusing Clenbuterol by overdosing in order to achieve a repartitioning effect, or to build muscle mass. That appears to be a non-issue in Standardbreds as they race too often for long-term dosages to be administered effectively. Dr. Tobin, a renowned expert from the University of Kentucky Gluck Equine Research Center, stated, “Clenbuterol did have a repartitioning effect and increased muscle mass, but this did not translate into an increase in performance. In fact, it decreased performance.” Although the prospect of catastrophic injury of racehorses was discussed, Dr. Tobin noted that “Harness Racing was one of the safest sports in North America. Only 1 in 15,000 fatal injuries occurred in Standardbreds, where 1 in 2,000 occurred in Thoroughbreds over the same time period.” Several other items were addressed, such as the list of 24 drugs that would provide for the basis of drugs that would have established levels for testing. All others would be considered “off-limits” for use and result in positive tests if found in race-day blood or urine testing. In addition, the proposal of special corticosteroid regulations sparked added debate. Of the nine speakers, eight of the experts gave convincing testimony toward the need for separate rules for each breed. Dr. Dionne Benson, the executive director of the RMTC (Racing Medication and Testing Consortium), was the last speaker and lone dissenter. She noted that the ad hoc committee for all breeds felt that the thresholds are appropriate, and that the state of Pennsylvania was “on-board” with her groups recommendations. Nonetheless, Joe Faraldo is not convinced that the RMTC proposals are suitable for Harness Racing. “We heard today that not all of the scientific bases have been covered. I believe that the [NYS Gaming Board] is cognizant of that fact. Because this board took the time to listen to all of these points of view, and the science behind them, it is a good indication that Harness Racing will be treated fairly.” by Chris Tully for Harnesslink.com
What has been described in some quarters as the biggest doping scandal in racing history occurred in England last month. The magnitude of the incident aside, there is a lesson to be learned from this notorious event that has little to do with doping. The message developed is this: Advocate for others only that which you truly practice yourself.
Darren Binskin is fuming with Harness Racing New South Wales officialdom after what he has termed a 'Miracle Mile' (A$750,000) disgrace. The Australian trainer now intends to confront them with all guns blazing in a hearing in Sydney at 2.30pm on Wednesday.
Due to an overwhelming positive response, Equine Guelph has opened registration for a second offering of their eWorkshop on colic prevention. Over 80 students from local and international background gained valuable knowledge over the course of 2 weeks in March to combat the number one killer of horses (other than old age!) with Equine Guelph's new eWorkshop on colic prevention.
In the Paulick Report’s “The Breeders’ Cup Forum: Lasix – A Racetrack Practitioner’s Perspective” (March 7, 2013), Dr. Don Shields, who has been a practicing veterinarian at Southern California racetracks for more than 25 years, makes a compelling argument for the use of furosemide (Lasix) to treat horses for exercise induced pulmonary hemorrhage (EIPH) in both training and racing.
The Board of Directors of Racing Commissions International has voted to move forward with a major revision of the association's model medication rules for horse racing.
The key to a horse's health lies beneath its appearance. A growing number of horse owners rely on the misconception that if their horse appears healthy and fit, then chances are it is. What if we had the tools to help us look beyond a horse's appearance so that good decisions could be made for its optimal health and management?
'Equine Stress and Transportation' is the over-arching theme of the upcoming Horse Management Seminar hosted by the Rutgers Equine Science Center and Rutgers Cooperative Extension. The seminar, scheduled from 8:00 am - 3:30 pm on Sunday, February 10, 2013, will feature presentations by several equine industry experts.
Colic is the number one killer of horses (other than old age!) and Equine Guelph is launching a comprehensive colic survey across Canada to better understand colic management practices in the industry and how people are dealing with colic. "Understanding the horse owners' experiences with colic will assist in developing targeted educational programs," says Gayle Ecker, director of Equine Guelph.
The time to expect thoroughbred and harness racing and its current regulatory framework of state commissions to reform medication policies has come and gone.
Whoever said that the road to hell is paved with good intentions must have been thinking about the horse racing industry.
At the most recent United States Trotting Association annual meeting in February, USTA President Phil Langley appointed a committee of harness racing horsemen and track operators to study drug testing and to investigate what the industry can do to improve testing procedures, including providing more financial support.
Other racing states may be affected by the stance of two New York senators who believe that the anti-bleeding medication furosemide, which is used in harness racing, should not be banned on race-day.